News


All News

The problem in the aesthetic marketplace is everyone offers the same thing, in the same way and says the same things, says one expert.

A new application of cyolipolysis proves to be an effective non-invasive option in the treatment of pseudogynecomastia, according to study.

Adalimumab (Humira, AbbVie) enhances both health-related quality of life and work productivity in patients with moderate-to-severe hidradenitis suppurativa, according to the results of two phase 3 clinical trials.

Long-term data for dupilumab in atopic dermatitis revealed at the American Academy of Dermatology (AAD) 75th Annual Meeting reflect safety, rapid relief of troublesome symptoms and a long-lived response in keeping with the drug’s breakthrough status, experts told Dermatology Times.

Patient education

In our last article “Building a Patient Education Program” (May, page 82) we explored how a solid patient education program can keep patients, resources and revenue from falling through the cracks and what your practice needs to build a strong patient education program.

An old anti-aging concept was rediscovered with the renewed popularity of facial patches.

Fitting in

The approval of dupilumab (Dupixent, Sanofi Regeneron) for moderate-to-severe atopic dermatitis adds a much-needed option that may alter the broader course of atopic disease, experts told Dermatology Times.

Revenue boosters

Dermatologists trying to boost practice revenue might add a device in hopes of making a profit on a cosmetic option or a skincare product line sold through the practice.

Castle Creek Pharmaceuticals announced in June 2017 that the first patient had enrolled in its phase 2/3 study assessing the safety and efficacy of its pipeline diacerein 1% ointment to treat epidermolysis bullosa simplex.

Glytone has released the Glytone Sunscreen Lotion Broad Specturm SPF 40 as a daily sunscreen to be used in combination with aesthetic procedures and treatments.

Key publications from the past year have enhanced our understanding of immunomodulatory drugs for advanced and metastatic skin cancers. Others could portend significant practice changes in areas such as sentinel lymph node (SLN) biopsy, says one dermatologist

IL-31 at center stage

A novel interleukin (IL) antagonist currently in phase 2 studies could advance the treatment of atopic dermatitis (AD), according to dermatologist.

Dermatologists and some psoriasis patients might soon grapple with switching from a biologic to a biosimilar.

Emerging data suggest that atopic dermatitis is not just a skin disease. In terms of its impact on the whole patient and its potential for multi-organ involvement, it is a systemic disease, according to one dermatologist.

SKs concern patients

A recent study suggests patients are bothered by seborrheic keratoses and are inclined to want the lesions removed. Dermatologist Gary Goldenberg talks about a new option in the pipeline and how best to treat these lesions with available therapies.

Nonthermal pulsed ultrasound (UltraShape, Syneron Candela) treatments significantly reduce flank fat, without pain, downtime and apparent risks, according to a study.

The clinical presentation of acne vulgaris in darker-skinned individuals differs in many ways from the white population, including some specific exacerbating factors that are due to cultural skin and hair-care practices.